Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Targeting Autophagy-Related Protein Kinases for Potential Therapeutic Purpose

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Targeting autophagy with small-molecule activators for potential therapeutic purposes

Targeting selective autophagy and beyond: From underlying mechanisms to potential therapies

Key Autophagic Targets and Relevant Small-Molecule Compounds in Cancer Therapy.

Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy

Drug discovery by targeting the protein‒protein interactions involved in autophagy

Autophagic Pathways As New Targets for Cancer Drug Development

Targeting autophagy drug discovery: Targets, indications and development trends

Untangling knots between autophagic targets and candidate drugs, in cancer therapy.

Autophagy Modulation in Cancer Therapy: Challenges Coexist with Opportunities

Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy

Therapeutic strategies targeting AMPK-dependent autophagy in cancer cells

Small‐Molecule Regulators of Autophagy and Their Potential Therapeutic Applications

Pharmaceutical Agents for Targeting Autophagy and Their Applications in Clinics

Targeting autophagy in disease: established and new strategies

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease

The Participation of Non-Canonical Autophagic Proteins in the Autophagy Process and Their Potential As Therapeutic Targets

Autophagy Intertwines with Different Diseases—Recent Strategies for Therapeutic Approaches

Autophagy Modulation As a Target for Anticancer Drug Discovery.

Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions